Gannex doses first subject in Phase II primary biliary cholangitis trial

Gannex Pharma has dosed the first subject in Phase II trial of ASC42 for the treatment of primary biliary cholangitis (PBC) patients.

Related Keywords

China ,Gannex Pharma ,Jinzi Wu ,Ascletis Pharma ,Laboratory Equipment ,China National Medical Products Administration ,Contract Manufacturing Organisation ,European Union ,Time Data Services For Clinical Research ,Drug Processing Technology ,Fibroblast Growth Factor ,Manufacturing Organisation ,Pharmaceutical Supply ,Time Data Services ,Clinical Research ,Processing Technology ,